GlassScriptPhysician profile
Channae Watkins
NPI 1578115234
$4,836.90
in general payments reported to CMS, 2019-2025
18 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $586 · 2023: $1,597 · 2024: $871 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,951 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,951.08 |
| Education | $104.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,437.84 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $852.59 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $382.84 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $367.69 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $342.68 | 2023-2025 | Rexulti |
| Neurelis, INC. | $311.84 | 2022-2024 | Valtoco |
| Axsome Therapeutics, INC. | $285.50 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $189.21 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $171.10 | 2021 | |
| Abbvie INC. | $137.08 | 2021-2025 | |
| Corium, LLC | $88.36 | 2025 | Azstarys |
| Lundbeck LLC | $77.80 | 2023-2025 | Rexulti |
| Dexcom, INC. | $58.46 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Almatica Pharma LLC | $46.25 | 2025 | Loreev Xr |
| Tris Pharma INC | $39.13 | 2023 | Dyanavel Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.53 | 2023 | Qelbree |
| Genentech USA, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Channae Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.